Literature DB >> 31135177

miR-15a-3p Suppresses Prostate Cancer Cell Proliferation and Invasion by Targeting SLC39A7 Via Downregulating Wnt/β-Catenin Signaling Pathway.

Yu Cui1, Yi Yang2, Liang Ren3, Jun Yang4, Bin Wang1, Tianjun Xing1, Huiqing Chen1, Mingxiao Chen5.   

Abstract

Background: MiR-15a-3p has been reported as a tumor suppressor in several kinds of cancer, including cervical cancer and gastric cancer. However, the precise molecular mechanisms underlying its role in prostate cancer (PCa) remain largely unknown.
Methods: The expression of miR-15a-3p was determined in PCa tissues and cell lines using quantitative real time PCR. The biological function of miR-15a-3p in PCa cells was investigated using a MTT assay, Edu staining and transwell assay. Moreover, luciferase reporter assay, quantitative real time PCR and western blotting were used to identify and verify the direct downstream target of miR-15a-3p.
Results: We found that the expression of miR-15a-3p was down-regulated in both PCa tissues and cell lines. The in vitro results showed that miR-15a-3p overexpression suppressed cell proliferation, invasion, and epithelial-mesenchymal transition (EMT) via down-regulating Wnt/β-catenin signaling in PCa cells. Moreover, SLC39A7 was a direct downstream target of miR-15a-3p. Furthermore, SLC39A7 overexpression attenuated the effects of miR-15a-3p on cell proliferation, invasion, Wnt/β-catenin pathway and EMT molecules. Conclusions: In summary, our study indicated that miR-15a-3p inhibited the proliferation, invasion, and EMT process of PCa cells via targeting SLC39A7 and suppressing Wnt/β-catenin signaling pathway, which may represent a new therapeutic objective for PCa treatment.

Entities:  

Keywords:  EMT; SLC39A7; Wnt/β-catenin; miR-15a-3p; prostate cancer

Mesh:

Substances:

Year:  2019        PMID: 31135177     DOI: 10.1089/cbr.2018.2722

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  8 in total

1.  MicroRNA-15a promotes prostate cancer cell ferroptosis by inhibiting GPX4 expression.

Authors:  Po Xu; Ying Wang; Zhe Deng; Zhibo Tan; Xiaojuan Pei
Journal:  Oncol Lett       Date:  2022-01-03       Impact factor: 2.967

2.  Evaluation of the prognostic values of solute carrier (SLC) family 39 genes for patients with lung adenocarcinoma.

Authors:  Heng Zhou; Yaoqi Zhu; Huizhong Qi; Liang Liang; Hao Wu; Jingping Yuan; Qingyong Hu
Journal:  Aging (Albany NY)       Date:  2021-02-01       Impact factor: 5.682

3.  LncRNA LUADT1 sponges miR-15a-3p to upregulate Twist1 in small cell lung cancer.

Authors:  Dingxue Wang; Wenyu Wu; Wenqi Huang; Jinghui Wang; Li Luo; Dongxin Tang
Journal:  BMC Pulm Med       Date:  2019-12-16       Impact factor: 3.317

Review 4.  MicroRNAs target the Wnt/β‑catenin signaling pathway to regulate epithelial‑mesenchymal transition in cancer (Review).

Authors:  Yuhe Lei; Lei Chen; Ge Zhang; Aiyun Shan; Chunfeng Ye; Bin Liang; Jiayu Sun; Xin Liao; Changfeng Zhu; Yueyue Chen; Jing Wang; Enxin Zhang; Lijuan Deng
Journal:  Oncol Rep       Date:  2020-07-23       Impact factor: 3.906

Review 5.  Wnt/β-catenin signal transduction pathway in prostate cancer and associated drug resistance.

Authors:  Chunyang Wang; Qi Chen; Huachao Xu
Journal:  Discov Oncol       Date:  2021-10-10

6.  Comprehensive Analysis of Histone Modifications in Hepatocellular Carcinoma Reveals Different Subtypes and Key Prognostic Models.

Authors:  Huikai Li; Han Mu; Yajie Xiao; Zhikun Zhao; Xiaoli Cui; Dongfang Wu
Journal:  J Oncol       Date:  2022-08-01       Impact factor: 4.501

7.  Prostate Cancer Secretome and Membrane Proteome from Pten Conditional Knockout Mice Identify Potential Biomarkers for Disease Progression.

Authors:  Nilton J Santos; Ana Carolina Lima Camargo; Hernandes F Carvalho; Luis Antonio Justulin; Sérgio Luis Felisbino
Journal:  Int J Mol Sci       Date:  2022-08-17       Impact factor: 6.208

8.  LINC_00355 promotes gastric cancer progression by upregulating PHF19 expression through sponging miR-15a-5p.

Authors:  Jishui Zhang; Wenhao Lv; Yagang Liu; Weihua Fu; Baosheng Chen; Qiutong Ma; Xin Gao
Journal:  BMC Cancer       Date:  2021-06-02       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.